Drug intelligence / Profile preview

EA5

Development stage: Phase 1
Lead developer: Shanghai Lanyi Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EA5 is a humanized monoclonal antibody developed by Shanghai Lanyi Therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It functions as a complement inhibitor by specifically targeting complement component 5 (C5). By binding to C5, EA5 prevents its enzymatic cleavage into the pro-inflammatory mediator C5a and the initiator of the terminal complement pathway, C5b. This blockade prevents the formation of the membrane attack complex (MAC), thereby protecting PNH-affected red blood cells from intravascular hemolysis. EA5 is currently being evaluated in Phase Ib clinical trials to determine its safety, pharmacokinetic, and pharmacodynamic profiles in adult patients with PNH.

Brand names: EA5EA-5EA 5
Other names: EA5EA-5EA 5

Targets

Beyond the preview

Go deeper on EA5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EA5.

Explore the full profile